Dihydrocodeine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using the report structure specified in the task prompt (no additional skill applies — this is a direct content-generation task from a supplied Evidence Pack). Below is the generated report.
Dihydrocodeine: From Analgesic/Antitussive Use to Nasal Cavity Disease
One-Sentence Summary
Dihydrocodeine is an opioid analgesic and antitussive (μ‑opioid receptor agonist) with no SAHPRA registration currently on file for the South African market. The TxGNN model’s top-ranked prediction is Nasal Cavity Disease, but this is supported by 0 clinical trials and 0 publications, and the evidence pack itself characterizes the proposed mechanistic link as indirect, non-specific, and weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not captured in structured registry data (no SAHPRA/TFDA indication text on file). Known pharmacologically as an opioid analgesic / antitussive (μ‑opioid receptor agonist), per the repurposing rationale notes in this evidence pack |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.99% (0.99991), model rank 120 |
| Evidence Level | L5 (model prediction only — no clinical trials, no literature) |
| South Africa Market Status | Not marketed (未上市) |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this drug (flagged in the evidence pack as a High-severity data gap, DG002). Based on the information that is available, Dihydrocodeine is a μ‑opioid receptor agonist with established analgesic and antitussive (cough-suppressant) pharmacology.
The evidence pack’s own repurposing rationale for Nasal Cavity Disease states that there is “no known direct pathological mechanistic connection between nasal cavity disease (structural/inflammatory) and the opioid receptor pathway”; the only plausible link is that Dihydrocodeine’s antitussive action might indirectly relieve cough associated with post-nasal drip in some nasal conditions. This is explicitly described as an “extremely indirect, non-specific connection with weak evidence.”
In short, this prediction rests on graph-based pattern similarity from TxGNN rather than a validated pharmacological hypothesis. No clinical trials or peer-reviewed literature currently support treating nasal cavity disease with Dihydrocodeine, and the mechanistic story is speculative at best.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Dihydrocodeine currently has no SAHPRA registrations on file (total_licenses = 0; market_status = Not marketed). No product registration number, brand name, dosage form, or approved indication text is available from the source data used to build this evidence pack.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Important context from this evidence pack:
- Blocking data gap: TFDA/SAHPRA package-insert warnings and contraindications are not yet available (DG001, severity: Blocking). Per the evidence pack, this means the candidate cannot proceed to an initial safety (S1) assessment until package-insert data is obtained.
- Class-level caution (opioid): Dihydrocodeine is a μ‑opioid receptor agonist. Standard opioid-class concerns — respiratory depression, dependence/abuse potential, and constipation — apply generally to this class, though drug-specific data was not available in this pack. One retrieved publication (PMID 11915306, on a related dihydrocodeine-containing cough syrup) documents abuse and dependence associated with dihydrocodeine-containing products.
Other TxGNN Candidates Reviewed (Screening Context)
This evidence pack scored 10 candidate indications for Dihydrocodeine; all currently sit at decision stage S0 with a “Hold” recommendation. Several are worth flagging explicitly because the underlying mechanistic rationale is a safety caution, not a treatment opportunity:
| Rank | Disease | Score | Note |
|---|---|---|---|
| 3 | Allergic urticaria | 99.92% | The rationale flags that opioids (incl. Dihydrocodeine) can trigger non-receptor-mediated mast cell degranulation and histamine release — this may worsen, not treat, urticaria. TxGNN’s high score likely reflects graph proximity to an adverse-effect node, not therapeutic potential. |
| 8 | Cold urticaria | 99.21% | Same histamine-release concern as above. |
| 10 | Atopic conjunctivitis | 98.78% | IgE-mediated allergic condition; same histamine-release caution applies. |
| 6 | Cervical disc degenerative disorder | 99.32% | Mechanistically plausible as non-specific analgesia (opioid for musculoskeletal/neuropathic pain), but no trials or literature exist for this specific indication. |
| 7 | Headache disorder | 99.26% | 2 supporting publications retrieved (evidence level L4), but neither supports efficacy — one is an abuse case series, the other an unrelated Cochrane index. Major headache guidelines (e.g., AHS/AAN) explicitly recommend against opioids for headache due to medication-overuse-headache and dependence risk. |
| 1, 2, 4, 5, 9 | Nasal cavity disease, acute laryngopharyngitis, papillary conjunctivitis, faucial diphtheria, trigeminal autonomic cephalalgia | 98.79%–99.99% | No clinical trials or literature; mechanistic links range from weak/non-specific (symptomatic cough/pain relief) to absent. |
No candidate in this set has clinical trial or robust literature support. Several of the highest-scoring predictions appear to reflect the model’s proximity to adverse-effect/safety nodes rather than genuine therapeutic signal — this should be communicated clearly to any reviewer relying on the raw TxGNN score alone.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked prediction (Nasal Cavity Disease) has no clinical trial or literature support and rests on a mechanistic link the evidence pack itself describes as weak and indirect (Evidence Level L5).
- A Blocking data gap (missing TFDA/SAHPRA Professional Information) means this candidate cannot yet undergo a basic safety assessment, independent of the efficacy question.
To proceed, the following is needed:
- SAHPRA/TFDA-approved Professional Information (warnings, contraindications, drug interactions) to resolve the Blocking data gap (DG001)
- Detailed mechanism of action (MOA) data from DrugBank to properly evaluate the mechanistic rationale (DG002)
- Any preclinical or mechanistic literature specifically addressing Dihydrocodeine in nasal cavity disease, if it exists, to move beyond L5
- Given the histamine-release safety signal identified for the urticaria/conjunctivitis candidates, an explicit pharmacovigilance review before considering those candidates further, since the mechanistic link there points toward risk rather than benefit
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.